Skip to main content

Rituximab for Secondary Progressive Multiple Sclerosis

A Case Series

CNS Drugs volume 25, pages 607–613 (2011)Cite this article

Abstract

Background: While numerous substances have been developed for the treatment of relapsing-remitting multiple sclerosis over recent years, options are still limited for patients with secondary progressive multiple sclerosis (SPMS).

Objectives and Methods: In this observational study we present clinical and CSF findings in three patients with SPMS who were treated with rituximab for at least 15 months.

Results: During the observation period, no severe adverse effects occurred and the Expanded Disability Status Scale (EDSS) score stabilized in all patients after a dramatic increase over the previous years. In contrast to other publications, we showed that the time to reoccurrence of B cells was very variable and that serial CSF examinations in the course of treatment revealed a decline in intrathecal IgG synthesis.

Conclusion: Rituximab seems to be effective in active SPMS. Restitution of the pathogenic immune response after administration of rituximab is variable. Further studies are needed to determine the optimal dosage and timing for rituximab therapy in multiple sclerosis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig 1
Fig 2
Fig 3
Fig 4
Fig 5

References

  1. Stüve O, Kieseier BC, Hemmer B, et al. Translational research in neurology and neuroscience 2010: multiple sclerosis. Arch Neurol 2010; 67: 1307–15

    PubMed  Article  Google Scholar 

  2. Mix E, Meyer-Rienecker H, Hartung H, et al. Animal models of multiple sclerosis: potentials and limitations. Prog Neurobiol 2010; 92: 386–404

    PubMed  Article  Google Scholar 

  3. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63: 1779–87

    PubMed  Article  CAS  Google Scholar 

  4. Kappos L. Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult Scler 2004; 10 Suppl. 1: S46–55

    PubMed  Article  CAS  Google Scholar 

  5. Krapf H, Morrissey SP, Zenker O, et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005; 65: 690–5

    PubMed  Article  CAS  Google Scholar 

  6. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98–108

    PubMed  Article  Google Scholar 

  7. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66: 483–9

    PubMed  Article  Google Scholar 

  8. Waubant E. Spotlight on anti-CD 20. Int MS J 2008; 15: 19–25

    PubMed  CAS  Google Scholar 

  9. Chan AC, Carter PJ. Therapeutic antibodies for auto-immunity and inflammation. Nat Rev Immunol 2010; 10: 301–16

    PubMed  Article  CAS  Google Scholar 

  10. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443–8

    PubMed  Article  Google Scholar 

  11. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–88

    PubMed  Article  CAS  Google Scholar 

  12. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008; 7: 538–47

    PubMed  Article  CAS  Google Scholar 

  13. Hawker K, O’Connor P, Freedman MS, et al., OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4): 460–71

    PubMed  Article  CAS  Google Scholar 

  14. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of early clinical course. Brain 1989; 112: 1419–28

    PubMed  Article  Google Scholar 

  15. Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998; 4(3): 111–7

    PubMed  CAS  Google Scholar 

  16. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001; 7: 115–21

    PubMed  Article  CAS  Google Scholar 

  17. Goodin DS, Cohen BA, O’Connor P, et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcomittee of the American Academy of Neurology. Neurology 2008; 71(10): 766–73

    CAS  Google Scholar 

  18. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67: 707–14

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

No funding was received to conduct this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Affiliations

  1. Department of Neurology, University of Rostock, Rostock, Germany

    Paulus S. Rommer, Robert Patejdl, Alexander Winkelmann, Reiner Benecke & Uwe K. Zettl

  2. Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

    Paulus S. Rommer

Authors
  1. Paulus S. Rommer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Patejdl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander Winkelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reiner Benecke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uwe K. Zettl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paulus S. Rommer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rommer, P.S., Patejdl, R., Winkelmann, A. et al. Rituximab for Secondary Progressive Multiple Sclerosis. CNS Drugs 25, 607–613 (2011). https://doi.org/10.2165/11589390-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11589390-000000000-00000

Keywords

  • Mitoxantrone
  • Expand Disability Status Scale
  • Alemtuzumab
  • Natalizumab
  • Daclizumab